Showing results 2 to 5 of 5
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
2021 | |||
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma Journal:Clinical Cancer Research | 2018 | ||
2017 | |||
A randomized, double-blind, multicenter phase 3 study of brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization in patients with unresectable hepatocellular carcinoma: initial results Proceeding/Conference:Annual Conference of the International Liver Cancer Association, ILCA 2013 | 2013 |